Aliskiren: An oral renin inhibitor for the treatment of hypertension

Cardiology in Review

Volumn 15, Issue 6, 2007, Pages 316-323

  Lam, Sum ^a,b   Choy, Mary ^a,c  

^a ST JOHN'S UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Aliskiren; Angiotensin; Hypertension; Renin inhibitor

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BENAZEPRIL; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; EPROSARTAN; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; RENIN; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ABDOMINAL PAIN; ANEMIA; ANGIONEUROTIC EDEMA; BACKACHE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; CHEST TIGHTNESS; CLINICAL TRIAL; COUGHING; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EDEMA; FATIGUE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GOUT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; MYOSITIS; NEPHROLITHIASIS; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTECTION; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TONIC CLONIC SEIZURE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URIC ACID BLOOD LEVEL; WEAKNESS;

ADMINISTRATION, ORAL; AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; RENIN; TREATMENT OUTCOME;

EID: 37349035236     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31814852a4     Document Type: Review

References (35)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2007;115:e69-e171.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-2572.
3. American Heart Association. High blood pressure. Available at: http://www.americanheart.org. Accessed April 3, 2007.
4. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. Lancet. 2000;356:1955-1964.
5. American Diabetes Association. Standards of Medical Care in Diabetes - 2007 (Position statement). Diabetes Care. 2007;30(Suppl 1):S4.
6. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: kidney disease outcome quality initiative. Am J Kidney Dis. 2002;39(Suppl 2):S1-S246.
7. Saseen JJ, Carter BL. Hypertension. In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Dipiro's Pharmacotherapy: A Pathophysiologic Approach. 6th ed. New York, NY: McGraw-Hill; 2005:185-217.
8. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670.
9. Tekturna, Aliskiren Tablets. [product information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
10. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449-1456.
11. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
12. Weber MA, Neutel JM, Essinger I, et al. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation. 1990;81:1768-1774.
13. Neutel JM, Luther RR, Boger RS, et al. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J. 1991;122:1094-1100.
14. Rongen GA, Lenders JW, Smits P, et al. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet. 1995;29:6-14.
15. Kleinbloesem CH, Weber C, Fahrner E, et al. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clin Pharmacol Ther. 1993;53:585-592.
16. Kobrin I, Viskoper RJ, Laszt A, et al. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens. 1993;6:349-356.
17. Ménard J, Boger RS, Moyse DM, et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation. 1995;91:330-338.
18. Frishman WH, Shanik MH, Lin C. Specific inhibitors of renin in cardiac therapy. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmaco-Therapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:589-600.
19. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitors. Biochem Biophys Res Commun. 2003;308:698-705.
20. Sepehrdad R, Frishman WH, Stier CT Jr, et al. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren. Cardiol Rev. 2007;15:242-256.
21. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
22. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
23. Wood JM, Schnell CR, Cumin F, et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417-426.
24. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
25. Vaidyanathan S, Warren V, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibition aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007;47:192-200.
26. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006;45:1125-1134.
27. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143.
28. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
29. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
30. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226.
31. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49:276-284.
32. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43:527-535.
33. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;58:433-436.
34. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract. 2006;60:1343-1356.
35. Drug price inquiry. Available at: http://www.drugstore.com/pharmacy. Accessed May 10, 2007.